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Sustained Chronic Obesity Results in Chronic 
Stretch, Diffuse Interstitial Fibrosis, Conduction 
Abnormalities, and Increased Vulnerability to AF
In an animal study, 10 chronically obese sheep, compared 
with 10 age-matched controls, demonstrated greater total 
body fat, left atrial (LA) volume, LA pressure, and pulmo-
nary artery pressures, reduced atrial conduction velocity with 
increased conduction heterogeneity, increased fractionated 
electrograms, decreased posterior LA voltage, and increased 
voltage heterogeneity (all p <0.001), with no change in the ef-
fective refractory period (ERP) or ERP heterogeneity. Obesity 
was associated with more episodes (p=0.02), prolongation 
(p=0.01), and greater cumulative duration (p=0.02) of atrial 
fibrillation (AF). Epicardial fat infiltrated the posterior LA 
in the obese group (p <0.001), consistent with reduced en-
docardial voltage in this region. Atrial fibrosis (p=0.03) and 
atrial transforming growth factor (TGF)-β1 protein (p=0.002) 
were increased in the obese group. The authors concluded 
that obesity results in global biatrial endocardial remodeling, 
and increased propensity for AF (Mahajan R et al, J Am Coll 
Cardiol 2015;66:1-11).
An Increased Percentage of PVCs on 24-h Holter 
Monitor Confers a Decrease in LVEF, Increased 
Incident CHF, and Increased Mortality: PVCs might 
be an Important Cause of Occult or “Idiopathic” 
Cardiomyopathy and an Important Determinant  
of Incident CHF Among Those with Other Established 
CHF Risk Factors
Among 1,139 Cardiovascular Health Study (CHS) partici-
pants, with a normal LVEF and no history of CHF, randomly 
assigned to 24-h Holter monitoring, those in the upper quartile 
vs the lowest quartile of PVC frequency had a 3-fold greater 
odds of a 5-year decrease in LVEF (odds ratio - OR: 3.10; 
p=0.005), a 48% increased risk of incident CHF (HR: 1.48; 
p=0.02), and a 31% increased risk of death (HR: 1.31; p=0.01) 
during a median follow-up of >13 years. The specificity for 
the 15-year risk of CHF exceeded 90% when PVCs included 
at least 0.7% of ventricular beats. The population-level risk 
for incident CHF attributed to PVCs was 8.1%. The authors 
concluded that in a population-based sample, a higher fre-
quency of PVCs was associated with a decrease in LVEF, an 
increase in incident CHF, and increased mortality (Dukes JW 
et al, J Am Coll Cardiol 2015;66:101-109).
Excessive Atrial Ectopy and Short Atrial Runs Confer 
an Increased Risk of Stroke Beyond Atrial Fibrillation 
(AF): Undiscovered Incident AF, Thrombogenic Atrial 
Disease or an Increased Vascular Risk Profile?
15-year data from the Copenhagen Holter Study (678 pa-
tients, ages 55-75 years, with no prior history of cardio-vascular 
disease, stroke, or AF) showed that 99 (15%) individuals had 
excessive supraventricular ectopic activity (ESVEA), i.e. ≥30 
premature atrial contractions (PACs)/h daily or any runs of 
≥20 PACs. ESVEA was associated with ischemic stroke when 
censoring subjects at time of AF (hazard ratio -HR: 1.96) or 
when modeling AF as a time-varying exposure (HR: 2.0). 
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Among subjects with ESVEA who developed a stroke, ~14% 
had diagnosed AF before their stroke. The incidence of stroke 
in subjects with ESVEA and a CHA2DS2-VASc score ≥2 was 
2.4% per year, comparable to the risk observed in AF. The 
authors concluded that ESVEA may confer an increased risk 
of ischemic stroke beyond manifest AF. Stroke was more often 
the first clinical presentation, rather than AF (Larsen BS et 
al, J Am Coll Cardiol 2015;66:232–241).
Trends in Acute Aortic Dissection (AAD) Over 17 
Years: Patients with Type A AAD have been More 
Often Managed Surgically with Decreasing Mortality / 
Endovascular Repair is Increasingly Used at  
Referral Centers for Patients with Complicated  
Type B Dissection
Over 17-years, Registry data from 4,428 patients (AAD 
type: A, n=2,952; B, n=1,476) indicated no change in the 
presenting complaints of severe or worst-ever pain for type A 
(93%) and type B AAD (94%), nor in the incidence of chest 
pain (83% & 71%, respectively). Use of computed tomogra-
phy (CT) for diagnosis of type A increased from 46% to 73% 
(p <0.001), and surgical management from 79% to 90% (p 
<0.001). Endovascular management of type B increased from 
7% to 31% (p <0.001). Type A in-hospital mortality decreased 
significantly (31% to 22%; p <0.001), as surgical mortality 
(25% to 18%; p=0.003). There was no significant trend in 
in-hospital mortality in type B (12% & 14%) (Pape LA et al, 
J Am Coll Cardiol 2015;66:350–358).
Consensus & New Definition of Early Repolarization: Jp 
(the Peak of an End-QRS Notch and/or the Onset of an 
End-QRS Slur as a Measure) should be ≥0.1 mv, while 
ST Elevation is not a Required Criterion
According to a consensus paper, early repolarization is pre-
sent if all of the following criteria are met: 1) An end-QRS notch 
or slur on the downslope of a prominent R-wave. The notch 
and the onset of a slur should lie entirely above the baseline. 
2) Jp ≥0.1 mV in 2 or more contiguous ECG leads, excluding 
leads V1 to V3. 3) QRS duration <120 ms. ST-segment eleva-
tion in the absence of a slur or notch should not be reported 
as early repolarization. QRS duration should be measured 
using those leads that do not exhibit a notch or slur. Leads 
V1 to V3 have been excluded from the new definition of early 
repolarization to avoid confusion with the Brugada pattern, 
which is regarded by some as a form of early repolarization. 
Finally, they suggest that an upward-sloping ST-segment, 
followed by an upright T-wave in the presence of end-QRS 
notching or slurring, is benign, whereas early repolarization 
with a horizontal or downward-sloping ST-segment is poten-
tially more serious. The authors conclude that in view of the 
relatively high prevalence of the early repolarization pattern 
without ST-segment elevation in apparently healthy subjects, 
in the absence of syncope or a strong family history of juvenile 
SCD, the finding of early repolarization does not merit further 
investigation, irrespective of ST-segment slope (Macfarlane PW 
et al, J Am Coll Cardiol 2015;66:470-477).
RITA-3 Trial: The Advantage of Reduced Mortality  
of a Routine Invasive vs a Selective Invasive Strategy  
in Non–ST-Segment Elevation Acute Coronary 
Syndrome Seen at 5 Years Attenuated at 10 Years
RITA-3 trial comparing outcomes of a routine early invasive 
strategy to those of a selective invasive strategy (for recurrent 
ischemia only) in patients with non–ST-segment elevation acute 
coronary syndrome (NSTEACS) showed a 24% reduction of 
all-cause mortality of the routine invasive strategy at a median 
of 5 years. At 10-years, among 1,810 patients with NSTEACS, 
there were no differences in mortality between the 2 groups. 
Risk of death varied markedly from 14.4% in the low-risk group 
to 56.2% in the high-risk group. This mortality trend did not 
depend on the assigned treatment strategy (Henderson RA 
et al, J Am Coll Cardiol 2015;66:511-520).
PROSE-ICD: Among Patients Undergoing Primary 
Prevention ICD Implantation, 40% Showed an 
Improved LVEF During Follow-Up, and in 25%,  
LVEF Improved to >35%
Among 538 patients having an ICD for primary preven-
tion of sudden cardiac death, over a mean follow-up of 4.9 
years, LVEF decreased in 13%, improved in 40%, and was 
unchanged in 47% of the patients. Comparing patients with 
an improved LVEF with those with an unchanged LVEF, the 
hazard ratios were 0.33 for mortality and 0.29 for appropriate 
shock. During follow-up, 25% of patients showed an improve-
ment in LVEF to >35% and their risk of appropriate shock 
decreased but was not eliminated (not enough to warrant 
deferring ICD generator replacement) (Zhang Y et al, J Am 
Coll Cardiol 2015;66:524-531).
ACTION Registry–GWTG: ~1/4 of Older Patients With 
AF who Undergo Coronary Stenting after Acute MI in 
the US are Discharged on DAPT plus an Anticoagulant 
(Triple Therapy) and Have Similar Rates of MACE 
but Significantly Greater Risk of Bleeding, Including 
Intracerebral Hemorrhage
Among 4,959 patients ≥65 years of age with acute MI and 
AF who underwent coronary stenting, 27.6% (n=1,370) were 
discharged on triple therapy (dual antiplatelet therapy - DAPT 
plus warfarin). Relative to DAPT, patients on triple therapy 
had a similar risk of MACE (hazard ratio - HR: 0.99) but 
significantly greater risk of bleeding requiring hospitalization 
(HR: 1.61) and greater risk of intracranial hemorrhage (HR: 
2.04) (Hess CN et al, J Am Coll Cardiol 2015;66:616-627).
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Like Hyponatremia, Hypochloremia in Patients 
Hospitalized for Acute Decompensated Heart Failure 
(ADHF) is Independently Associated With Long-Term 
Mortality
Among 1,318 consecutive patients with chronic heart failure 
admitted for ADHF and also in an independent ADHF cohort 
(n=876), admission serum chloride levels were independently 
and inversely associated with long-term mortality (hazard ratio 
- HR per unit change: 0.94; p <0.001), and in multivariable 
analysis remained independently associated with mortality 
(HR: 0.93; p <0.001) in contrast to admission sodium levels, 
which were no longer significant (p >0.05) (Grodin JL et al, 
J Am Coll Cardiol 2015;66:659-666).
APPRAISE-2 Trial: in Patients with Acute Coronary 
Syndrome (ACS), no Benefit and Greater Bleeding with 
Apixaban Given Concomitantly with Aspirin or with 
the Combination of Aspirin plus Clopidogrel
A total of 7,364 high-risk ACS patients treated with as-
pirin (n=1,202 or 16.3%) or aspirin plus clopidogrel (in = 
5,814 or 79%) were randomized to apixaban 5 mg twice daily 
or placebo. No differential effect of apixaban vs placebo was 
observed for the composite endpoint (cardiovascular death, 
MI, and ischemic stroke) in patients taking aspirin (12.21 vs 
13.21 per 100 patient-years; hazard ratio - HR: 0.91) or aspirin 
plus clopidogrel (13.22 vs 14.24; HR: 0.95). Compared with 
placebo, apixaban increased major bleeding in patients taking 
aspirin (1.48 vs 0.25; HR: 6.62) and in patients taking aspirin 
plus clopidogrel (2.58 vs 1.02; HR: 2.44). Similar results were 
obtained and in patients treated with and without PCI. The 
authors concluded that post-ACS treatment with apixaban vs 
placebo showed no efficacy, but it increased bleeding regard-
less of concomitant therapy with aspirin alone or aspirin plus 
clopidogrel (Hess CN et al, J Am Coll Cardiol 2015;66:777-787). 
IPAC Study: Most Women Presenting With Peri-
partum Cardiomyopathy (PPCM) Recover Myocardial 
Function Completely With Conventional Heart Failure 
Therapy During the First Year Post-Partum / Women 
With More Severe LV Dysfunction or Dilation at 
Presentation Have Less Chance of Full Recovery
100 women with PPCM were followed through 1 year post-
partum. Among them 30% were black, 65% white, 5% other; 
mean age 30±6 years; 88% were receiving beta-blockers and 
81% angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers. The LVEF at study entry was 0.35±0.10, 
0.51±0.11 at 6 months, and 0.53±0.10 at 12 months. By 1 year, 
13% had experienced major events or had persistent severe 
cardiomyopathy with an LVEF <0.35, and 72% achieved an 
LVEF ≥0.50. An initial LVEF <0.30, an LVEDD ≥6 cm, black 
race, and presentation after 6 weeks post-partum were associ-
ated with a lower LVEF at 12 months. No subjects with both 
a baseline LVEF <0.30 and an LVEDD ≥6 cm recovered by 
1 year, whereas 91% with both a baseline LVEF ≥0.30 and an 
LVEDD <6 cm recovered (p <0.00001) (McNamara DM et 
al, J Am Coll Cardiol 2015;66:905-914).
CARDIO-FIT Study: Increased Cardiorespiratory 
Fitness is Synergistic With Weight Loss as Part of 
the Management Strategy for Rhythm Control in 
Overweight and Obese Patients With AF 
Of 308 patients with atrial fibrillation (AF) and a body 
mass index ≥27 kg/m2 offered risk factor management and 
participation in a tailored exercise program, 95 patients had 
low, 134 adequate, and 79 high cardio-respiratory fitness at 
baseline. Over 49±19 months, total arrhythmia-free survival 
rates was 17% in the low, 76% in the adequate, and 84% in 
the high cardiorespiratory fitness groups (p <0.001). On mul-
tivariable analysis, the low cardiorespiratory fitness (hazard 
ratio - HR: 5.94; p <0.001) and no weight loss group (HR: 
3.64) remained an independent predictor of AF recurrence. 
Arrhythmia-free survival with and without rhythm control 
strategies was greatest in patients with high cardiorespiratory 
fitness (p <0.001). AF burden and symptom severity decreased 
significantly in the group with cardiorespiratory fitness gain 
≥2 METs as compared to <2 METs group (p <0.001). The 
authors concluded that cardiorespiratory fitness predicts ar-
rhythmia recurrence in obese individuals with symptomatic 
AF. Improvement in cardiorespiratory fitness augments the 
beneficial effects of weight loss (Pathak RK et al, J Am Coll 
Cardiol 2015;66:985-996). 
PREVEND Study: Despite Considerable Progress in 
Management of Cardiovascular Disease, the Incidence 
of AF has not Decreased, and is Associated With 
Adverse Cardiovascular Outcomes, Including Heart 
Failure and Stroke / Obesity Has Emerged as  
an Additional Risk Factor for AF
Among 8,265 Dutch participants over 9.7±2.3 years of 
follow-up, 265 participants developed AF (overall AF incidence 
of 3.3 per 1,000 person-years). Advancing age, male gender, 
antihypertensive drug use, higher body mass index, previous 
myocardial infarction, and previous stroke were associated 
with AF. AF was associated with cardiovascular events (hazard 
ratio - HR: 2.24; p=0.035), heart failure with either reduced 
or preserved ejection fraction (HR: 4.52; p <0.001), and all-
cause mortality (HR: 3.02; p <0.001) (Vermond RA et al, J 
Am Coll Cardiol 2015;66:1000-1007). 
Successful Initial Experience of Transapical 
Mitral Valve Replacement (TMVR) With a Novel 
Transcatheter Mitral Valve 
The first 3 patients (mean age 71±9 years, 2 men; EF 25-
30%) who had successful TMVR (Edwards FORTIS device) 
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via a transapical approach in Canada, had improvement in 
functional status, in exercise capacity, and in quality of life. At 
6-month follow-up, all 3 patients remain alive, without hospital 
readmission for heart failure and with NYHA functional class 
≤II (Altisent OA et al, J Am Coll Cardiol 2015;66:1011-1019).
Percutaneous Pericardiocentesis With Continuous 
Drainage for 3-5 Days is a Safe and Effective Strategy 
for Pericardial Effusion (PE) Management in Patients 
With Cancer, Even in Presence of Thrombocytopenia
Of 1,645 cancer patients referred for pericardial effusion 
(PE), 212 (13%) underwent pericardiocentesis, which was 99% 
successful with no procedural deaths. Four patients had major 
procedure-related bleeding independently of platelet count. 
Patients with catheter drainage for 3-5 days had the lowest 
recurrence rate (10%). Median overall survival was 143 days; 
older age (i.e., >65 years), lung cancer, platelet count<20,000/
μl, and malignant pericardial fluid were independently associ-
ated with poor prognosis. Patients with lung cancer, but not 
those with breast cancer, with proven malignant effusions had a 
significantly shorter median 1-year survival compared with those 
with nonmalignant effusions (16% vs 49%, respectively; p=0.01) 
(El Haddad D et al, J Am Coll Cardiol 2015;66:1119-1128). 
The Age Threshold (65 Years) Used in the CHA2DS2-
Vasc System for Initiating Oral Anticoagulants (OACs) 
May Be Lower (50 Years), at Least in Taiwanese Atrial 
Fibrillation (AF) Patients
Among 186,570 non-anticoagulated AF Taiwanese pa-
tients, the annual risk of ischemic stroke for males <65 years 
(CHA2DS2-VASc score 0; n=9,416) was 1.15% and females 
(score 1; n=6,390) 1.12%, and continuously increased from 
younger to older age groups, with an increment in stroke risk 
evident for patients >50 years of age. At a cutoff of 50 years, 
patients (both males and females) could be further stratified 
into 2 subgroups with different stroke risks (>50 years: 1.78%/
year; vs<50 years: 0.53%/year). The authors concluded that for 
Taiwanese patients 50-64 years of age, the annual stroke risk 
was 1.78%, which may exceed the threshold for OAC use for 
stroke prevention, while this was only 0.53% for AF patients 
<50 years of age, a truly low-risk obviating the need for OACs 
(Chao T-F et al, J Am Coll Cardiol 2015;66:1339-1347). 
CHANCE Trial: The Early (90-Day) Benefit  
of Clopidogrel and Aspirin in Decreasing Stroke  
Risk is Maintained at 1 Year
The CHANCE trial showed that treatment with clopidogrel 
and aspirin decreases the 90-day risk of stroke without increasing 
bleeding risk among 5170 patients randomly assigned within 
24 hours after onset of minor stroke or high-risk transient 
ischemic attack to clopidogrel-aspirin therapy or to aspirin-
alone. At 1-year, stroke occurred in 275 (10.6%) patients in 
the clopidogrel-aspirin group, in comparison with 362 (14%) 
patients in the aspirin group (hazard ratio, 0.78; P=0.006). 
Moderate or severe bleeding occurred in 7 (0.3%) patients in the 
clopidogrel-aspirin group and in 9 (0.4%) patients in the aspirin 
group (P=NS) (Wang Y et al, Circulation 2015;132:40-46).
Review & Meta-Analysis: Direct Oral Anticoagulants 
(DOACs) Have Equal Efficacy to Vitamin K 
Antagonists (VKA) in Managing Thrombotic Risks in 
the Elderly With Atrial Fibrillation (AF), but Different 
Bleeding Patterns 
Review and meta-analysis of 11 randomized trials of direct 
oral anticoagulants (DOACs) (dabigatran, apixaban, rivar-
oxaban, and edoxaban) reporting data for the elderly (>75 
years) for efficacy and bleeding outcomes in comparison with 
VKA during treatment for acute venous thromboembolism 
or stroke prevention in AF, indicated similar or superior to 
VKA efficacy in managing thrombotic risks for each DOAC. 
A nonsignificantly higher risk of major bleeding than with 
VKA was observed with dabigatran 150 mg (odds ratio-OR, 
1.18) but not with the 110-mg dose. There were significantly 
higher gastrointestinal bleeding risks with dabigatran 150 mg 
(OR 1.78) and dabigatran 110 mg (OR 1.40) and lower intrac-
ranial bleeding risks than VKA for dabigatran 150 mg (OR 
0.43) and dabigatran 110 mg (OR 0.36). A significantly lower 
major bleeding risk in comparison with VKA was observed for 
apixaban (OR 0.63), edoxaban 60 mg (OR 0.81), and 30 mg 
(OR 0.46), whereas rivaroxaban showed similar risks (Sharma 
M et al, Circulation 2015;132:194-204). 
Danish Cohort Study: Restarting Anticoagulant 
Treatment After Intracranial Hemorrhage in Patients 
With Atrial Fibrillation (AF) Confers Lower Risk of 
Recurrent Stroke &  Mortality Than not Restarting
Among 1752 patients with AF on oral anticoagulant treat-
ment with incident intracranial hemorrhage, at 1 year of 
follow-up, the rate of ischemic stroke/systemic embolism 
and all-cause mortality (per 100 person-years) for patients 
treated with oral anticoagulants was 13.6 (hazard ratio 0.55), 
in comparison with 27.3 for nontreated patients and 25.7 for 
patients receiving antiplatelet therapy. The rate of recurrent 
intracranial hemorrhage for patients treated with oral antico-
agulants was 8, in comparison with 8.6 for nontreated patients 
and 5.3 for patients receiving antiplatelet therapy. The authors 
concluded that oral anticoagulant treatment was associated with 
a significant reduction in ischemic stroke/all-cause mortality 
rates, supporting oral anticoagulant treatment reintroduction 
after intracranial hemorrhage as feasible (Nielsen PB et al, 
Circulation 2015;132:517-525).
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Fibrosis of the Papillary Muscles and Inferobasal Left 
Ventricular Wall May be the Arrhythmic Substrate of 
Mitral Valve Prolapse (MVP)
Cardiac pathology of 43 (7%) MVP patients out of 650 
young (≤40 years) adults with sudden cardiac death (SCD) (26 
females; age 19–40 years, median 32 years) showed bileaflet 
involvement in 70%, left ventricular fibrosis at the level of 
papillary muscles in all, and inferobasal wall in 88%. Among 
12 cases with available ECG, 10 (83%) had inverted T waves on 
inferior leads, and all had right bundle-branch block (RBBB) 
ventricular arrhythmias (VAs). Living patients with MVP with 
(n=30) and without (control subjects; n=14) complex VAs 
underwent contrast-enhanced cardiac magnetic resonance. 
Patients with either RBBB type or polymorphic complex VAs 
(22 females; age range, 28–43 years; median, 41 years), showed 
a bileaflet involvement in 70% of cases. Left ventricular late 
enhancement was identified by contrast-enhanced cardiac 
magnetic resonance in 93% of patients vs 14% of control 
subjects (P<0.001). The authors concluded that fibrosis of the 
papillary muscles and inferobasal left ventricular wall is the 
structural substrate for VAs origin, and that contrast-enhanced 
cardiac magnetic resonance may help to identify this concealed 
substrate (Basso C et al, Circulation 2015;132:7 556-566).
Extracranial Systemic Embolic Events (SEEs) 
Constitute 11.5% of Clinically Recognized Thrombo-
embolic Events in Patients with AF and are Associated 
with High Morbidity and Mortality
A total of 221 extracranial systemic embolic events (SEEs) 
in 219 patients were reported among 37,973 patients in 4 ran-
domized clinical trials of anticoagulation in AF over 91,746 
patient-years of follow-up. The SEE incidence was 0.24 of 100 
and stroke incidence was 1.92 of 100 patient-years. In com-
parison with patients with stroke, those with SEE were more 
often female (56% vs 47%; P=0.01) and had comparable mean 
age (73.1±8.5 vs 73.5±8.8 years; P=NS) and mean CHADS2 
scores (2.4±1.3 vs 2.5±1.2; P=0.33). SEEs more frequently 
involved the lower extremity (58%) than visceral-mesenteric 
(31%) or upper extremity (10%). Management comprised clinic 
assessment alone in 5%, hospitalization in 30%, endovascular 
or surgical intervention in 60%, and amputation in 5%. Within 
30 days, 54% of patients recovered fully, 20% survived with 
deficits, and 25% died. Visceral-mesenteric SEE had higher 
mortality than lower- or upper-extremity SEE. The relative risk 
of death was 4.33 after SEE vs 6.79 after stroke (Bekwelem W 
et al, Circulation 2015;132:9 796-803).
REACH Registry: Severe 4-Year Impact of Diabetes 
Mellitus on Hospitalization for Heart Failure, 
Cardiovascular (CV) Events, and Death
Of the 45,227 patients in the REACH registry having 4-year 
follow-up, 43.6% (n=19,699) had diabetes (DM) at baseline. 
Overall risk and hazard ratio (HR) of CV death, nonfatal MI, 
or nonfatal stroke were greater in patients with DM (16.5% 
vs 13.1%; hazard ratio-HR, 1.27). There was also an increase 
in both CV death (8.9% vs 6%; HR, 1.38) and overall death 
(14.3% vs 9.9%; HR, 1.40). DM was associated with a 33% 
greater risk of hospitalization for heart failure (9.4% vs 5.9%; 
odds ratio - OR, 1.33). In diabetics, heart failure at baseline was 
independently associated with CV death (HR, 2.45; P<0.001) 
and hospitalization for heart failure (OR, 4.72; P<0.001) 
(Cavender MA et al, Circulation 2015;132:10 923-931).
Danish Registry: A Family History of Premature 
Cardiomyopathy Death is Associated With an Increase 
in Risk of Cardiomyopathy, Supporting Need for 
Screening of Relatives of Cardiomyopathy Patients
In a cohort of 3.9 million persons born from 1950 to 2008, 
3890 cardiomyopathies were identified in 89 million person-
years of follow-up. Premature cardiomyopathy deaths in 
first- and second-degree relatives were associated with 29- and 
6-fold increases in the rate of cardiomyopathy, respectively. 
If the first-degree relative died aged <35 years, the rate of 
cardiomyopathy increased 100-fold; given ≥2 premature deaths 
in first-degree relatives, the rate increased >400-fold, while a 
family history of premature death from other cardiac or non-
cardiac conditions increased the rate of cardiomyopathy only 
3-fold (Ranthe MF et al, Circulation 2015;132:11 1013-1019).
Endovascular Repair, Compared With Open Repair, of 
Abdominal Aortic Aneurysm (AAA) Confers an Early 
Survival Advantage but this Gradually Decreases Over 
Time, while the Rate of Late Rupture is Higher After 
Endovascular than After Open Repair
Among 39,966 matched pairs of patients with AAA who 
had undergone either open or endovascular repair, the overall 
perioperative mortality was 1.6% with endovascular vs 5.2% 
with open repair (P<0.001). Over time, perioperative mortality 
decreased by 0.8% among patients with endovascular repair 
(P=0.001) and by 0.6% in patients who underwent open repair 
(P=0.01). The rate of conversion from endovascular to open 
repair decreased from 2.2% in 2001 to 0.3% in 2008 (P<0.001). 
Survival was higher after endovascular vs open repair at the 
first 3 years of follow-up, but similar afterwards. At 8 years, 
interventions for the aneurysm or its complications were more 
common after endovascular repair, whereas interventions for 
complications related to laparotomy were more common after 
open repair. Aneurysm rupture occurred in 5.4% of patients 
after endovascular repair vs 1.4% of patients after open re-
pair (P<0.001) (Schermerhorn ML et al, N Engl J Med 2015; 
373:328-338). 
Idarucizumab for Dabigatran Reversal
A total of 90 patients received 5 g of IV idarucizumab be-
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cause of serious bleeding from dabigatran (group A, n=51) or 
because they required an urgent procedure (group B, n=39), 
and among 68 patients with an elevated dilute thrombin time 
and 81 with an elevated ecarin clotting time at baseline, the 
median maximum percentage reversal was 100%. Idarucizumab 
normalized the test results in 88-98% of patients within min-
utes. Concentrations of unbound dabigatran remained <20 
ng/ml at 24 hours in 79% of patients. Among 35 patients in 
group A being assessed, hemostasis was restored at a median 
of 11.4 hours. Among 36 patients in group B who underwent 
a procedure, normal intraoperative hemostasis was reported 
in 33, and abnormal hemostasis in 3 patients. One thrombotic 
event occurred within 3 days after idarucizumab in a patient 
in whom anticoagulants had not been reinitiated. The authors 
concluded that idarucizumab completely reversed the antico-
agulant effect of dabigatran within minutes (Pollack CV et al, 
N Engl J Med 2015; 373:511-520). 
BARI 2D Study: Abnormal Cardiac Troponin T is an 
Independent Predictor of Death from Cardiovascular 
Causes, MI, or Stroke in Diabetic Patients with Stable 
Ischemic Heart Disease, but does not Predict Benefit 
from Prompt Coronary Revascularization
Of the 2285 diabetic patients with stable ischemic heart 
disease, 2277 (99.6%) had detectable (≥3 ng per liter) high-
sensitivity troponin T and 897 (39.3%) had abnormal troponin T 
(≥14 ng per liter) at baseline. The 5-year rate of the composite 
end point (death from cardiovascular causes, MI, or stroke) was 
27.1% among patients with abnormal troponin T at baseline, 
as compared with 12.9% among those with normal baseline 
troponin T. The hazard ratio (HR) for the composite end 
point among patients with abnormal troponin T was 1.85 (P 
<0.001). Among patients with abnormal troponin T, random 
assignment to prompt revascularization, as compared with 
medical therapy alone, did not result in a significant reduction 
in the rate of the composite end point (HR, 0.96) (Everett BM 
et al, N Engl J Med 2015; 373:610-620). 
BRIDGE Trial: for Patients With AF who Require 
Temporary Interruption of Warfarin for an Elective 
Operation or Invasive Procedure, a Strategy with no 
Bridging was Noninferior to Perioperative Bridging 
with Low-Molecular-Weight Heparin for Prevention 
of Arterial Thromboembolism and also Decreased the 
Risk of Major Bleeding 
After perioperative interruption of warfarin, 1884 patients 
were randomly assigned to receive bridging anticoagulation 
with low-molecular-weight heparin (100 IU/kg of dalteparin) 
(n=934) or matching placebo (n=950) administered subcu-
taneously twice daily, from 3 days before the procedure until 
24 hours before the procedure and then for 5-10 days after 
the procedure. Warfarin was stopped 5 days before the pro-
cedure and was resumed within 24 hours later. The incidence 
of arterial thromboembolism at 30 days was 0.4% in the no-
bridging group and 0.3% in the bridging group (P=0.01 for 
noninferiority). The incidence of major bleeding was 1.3% in 
the no-bridging group and 3.2% in the bridging group (relative 
risk, 0.41; P=0.005 for superiority) (Douketis JD et al, N Engl 
J Med 2015; 373:823-833).
Takotsubo Registry: Takotsubo Cardiomyopathy 
Represents an Acute Heart Failure Syndrome With 
Substantial Morbidity and Mortality and Has a Higher 
Prevalence of Neurologic or Psychiatric Disorders than 
an Acute Coronary Syndrome 
Of 1750 patients with takotsubo cardiomyopathy, 89.8% 
were women (mean age, 66.8 years). Emotional triggers were 
present in 27.7% and physical triggers in 36%, while 28.5% 
of patients had no evident trigger. In patients with takot-
subo, as compared with an acute coronary syndrome, rates 
of neurologic or psychiatric disorders were higher (55.8% 
vs 25.7%) and the mean left ventricular ejection fraction 
was much lower (40.7±11.2% vs 51.5±12.3%) (P <0.001). 
Rates of severe in-hospital complications including shock 
and death were similar in the two groups. Physical triggers, 
acute neurologic or psychiatric diseases, high troponin levels, 
and a low ejection fraction on admission were independent 
predictors for in-hospital complications. During long-term 
follow-up, the rate of major adverse cardiac and cerebro-
vascular events was 9.9% per patient-year, and the rate of 
death was 5.6% per patient-year (Templin C et al, N Engl J 
Med 2015; 373:929-938). 
MATRIX Trial: in Patients With an Acute Coronary 
Syndrome, Rates of Major Adverse Cardiovascular 
Events Were not Significantly Lower with Bivalirudin 
than with Unfractionated Heparin, nor was the 
Composite of Urgent Target-Vessel Revascularization, 
Stent Thrombosis, or Adverse Clinical Events with a 
Post-PCI Bivalirudin Infusion 
A total of 7213 patients with an acute coronary syndrome 
for whom PCI was anticipated were randomized to either bi-
valirudin or unfractionated heparin; patients in the bivalirudin 
group were then randomly assigned to receive or not a post-PCI 
bivalirudin infusion. The rate of major adverse cardiovascular 
events (death, MI, or stroke) was not significantly lower with 
bivalirudin (10.3%) than with heparin (10.9%) (relative risk, 
0.94; P=NS), nor was the rate of net adverse clinical events 
(major bleeding or a major adverse cardiovascular event) 
(11.2% and 12.4%, respectively; relative risk, 0.89; P=NS). 
Post-PCI bivalirudin infusion, as compared with no infusion, 
did not significantly decrease the rate of urgent target-vessel 
revascularization, definite stent thrombosis, or net adverse 
clinical events (11% and 11.9%, respectively; relative risk, 0.91; 
P=NS) (Valgimigli M et al, N Engl J Med 2015; 373:997-1009). 
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CIRCUS Trial: Cyclosporin did not Attenuate 
Reperfusion Injury / In Patients With Anterior STEMI 
Referred for Primary PCI, Cyclosporine did not Result 
in Better Clinical Outcomes and did not Prevent 
Adverse Left Ventricular Remodeling at 1 Year
A total of 970 patients with an acute anterior ST-segment 
elevation myocardial infarction (STEMI) undergoing percuta-
neous coronary intervention (PCI) within 12 hours after symp-
tom onset, having complete occlusion of the culprit coronary 
artery, were randomized to a bolus injection of cyclosporine (2.5 
mg/kg) (n=395) or matching placebo (n=396) before coronary 
recanalization. The rate of the primary outcome, i.e. composite 
of death from any cause, worsening of heart failure during the 
initial hospitalization, rehospitalization for heart failure, or 
adverse left ventricular remodeling (increase of ≥15% in the 
left ventricular end-diastolic volume) at 1 year, was 59% in 
the cyclosporine group and 58.1% in the control group (odds 
ratio, 1.04; P=NS). Cyclosporine did not reduce the incidence 
of the separate clinical components of the primary outcome or 
other events, including recurrent infarction, unstable angina, 
and stroke. Safety profile was similar in the two groups (Cung 
T-T et al, N Engl J Med 2015; 373:1021-1031). 
LEADLESS II Study: Satisfactory Performance  
of the Leadless Pacemaker
An active-fixation leadless cardiac pacemaker was success-
fully implanted in 504 (95.8%) of 526 patients who required 
permanent single-chamber ventricular pacing. The intention-
to-treat primary efficacy end point (both an acceptable pacing 
threshold, i.e ≤2.0 V at 0.4 ms, and an acceptable sensing 
amplitude, i.e. R wave ≥5 mV) through 6 months was met in 
270 of the 300 patients in the primary cohort (90%, P=0.007), 
and the primary safety end point (freedom from device-related 
serious adverse events through 6 months) was met in 280 of 
the 300 patients (93.3%; P<0.001). At 6 months, device-
related serious adverse events were observed in 6.7% of the 
patients; events included device dislodgement with percuta-
neous retrieval (in 1.7%), cardiac perforation (in 1.3%), and 
pacing-threshold elevation requiring percutaneous retrieval 
and device replacement (in 1.3%) (Reddy VY et al, N Engl J 
Med 2015; 373:1125-1135).
3SITES Study: Complications of Central Venous 
Catheterization / Subclavian-Vein Catheterization was 
Associated with a Lower Risk of Bloodstream Infection 
and Symptomatic Thrombosis and a Higher Risk of 
Pneumothorax than Jugular-Vein or Femoral-Vein 
Catheterization
A total of 3471 catheters were inserted in 3027 ICU pa-
tients. There were 8, 20, and 22 primary outcome events 
(catheter-related bloodstream infection and symptomatic 
deep-vein thrombosis) in the subclavian, jugular, and femoral 
groups, respectively (1.5, 3.6, and 4.6 per 1000 catheter-days; 
P=0.02). In pairwise comparisons, the risk of the primary 
outcome was significantly higher in the femoral group than in 
the subclavian group (hazard ratio - HR, 3.5; P=0.003) and 
in the jugular group than in the subclavian group (HR, 2.1; 
P=0.04), whereas the risk in the femoral group was similar to 
that in the jugular group (HR, 1.3; P=0.30). Pneumothorax 
requiring chest-tube insertion occurred in association with 13 
(1.5%) of the subclavian-vein insertions and 4 (0.5%) of the 
jugular-vein insertions (Parienti J-J et al, N Engl J Med 2015; 
373:1220-1229). 
The Extent of Coronary Artery Calcification (CAC) 
Accurately Predicts 15-Year Mortality in a Large 
Cohort of Asymptomatic Patients 
Among 9715 asymptomatic patients, the coronary artery 
calcification (CAC) score, over median follow-up of 14.6 
years, was highly predictive of all-cause mortality (P<0.001). 
Overall 15-year mortality rates ranged from 3% to 28% for 
CAC scores from 0 to ≥1000 (P<0.001). The relative hazard 
for all-cause mortality ranged from 1.68 for a CAC score of 
1-10 (P<0.001) to 6.26 for a score of ≥1000 (P<0.001) (Shaw 
LJ et al, Ann Intern Med 2015;163:14-21).
Meta-Analysis: PCSK9 Monoclonal Antibody Therapy 
Seems to be a Safe and Effective Strategy for Patients 
with Dyslipidemia
Meta-analysis of 24 randomized trials comprising 10,159 
patients indicated that, compared with no antibody, treatment 
with PCSK9 antibodies led to marked reductions in LDL cho-
lesterol levels (mean difference, −47.49%; P <0.001) and other 
atherogenic lipid fractions, and it reduced all-cause mortality 
(odds ratio - OR, 0.45; P=0.015) and cardiovascular mortality 
(OR, 0.50; P=0.084). The rate of MI was significantly reduced 
with PCSK9 antibodies (OR, 0.49; P=0.030), and increases 
in the serum creatine kinase level were reduced (OR, 0.72; 
P=0.026). Serious adverse events did not increase with PCSK9 
antibodies (Navarese ER et al, Ann Intern Med 2015;163:40-51).
Meta-Analysis: Extended Dual-Antiplatelet Therapy 
(DAPT) is Associated with Approximately 8 Fewer 
Myocardial Infarctions per 1000 Treated Patients per 
Year but 6 More Major Bleeding Events than Shorter-
Duration DAPT
Analysis of 9 trials comprising 28,808 patients indicated 
that longer-duration DAPT decreased risk for myocardial 
infarction (risk ratio - RR, 0.73) and increased mortality (RR, 
1.19). There was evidence of increased risk for major bleeding 
with DAPT (RR, 1.63) (Spencer FA et al, Ann Intern Med 
2015;163:118-126).
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In Patients with Mild Heart Failure (NYHA Class II), 
LVEF ≤30%, QRS ≥120 ms, CRT-D Appears to be  
Cost-Effective Compared to ICD Alone when  
a Reduction in Mortality is Expected
Use of cardiac resynchronization therapy-defibrillator 
(CRT-D) in patients aged ≥65 years with a left ventricular 
ejection fraction (LVEF) of ≤30%, QRS duration of ≥120 
ms, and NYHA class I or II symptoms, increased life ex-
pectancy (9.8 years vs 8.8 years), QALYs (8.6 vs 7.6 years), 
and costs ($286,500 vs $228,600), yielding a cost per QALY 
gained of $61,700. The cost-effectiveness of CRT-D was most 
dependent on the degree of mortality reduction, device cost, 
battery life and patient’s age (Woo CY et al, Ann Intern Med 
2015;163:417-426).
North American Study of Arrhythmogenic Right 
Ventricular Cardiomyopathy (ARVC): Competitive 
Sport was Associated with a Two-Fold Increased Risk 
of Ventricular Tachyarrhythmia (VTA)/Death and 
Earlier Presentation of Symptoms, When Compared 
With Inactive Patients, and to Patients  
who Participated in Recreational Sport 
Among probands diagnosed with ARVC (n=108), category 
of sports participation, i.e. competitive (n=41), recreational 
(n=48), and inactive (n=19) determined prognosis. Competi-
tive sport was associated with a significantly higher risk of VTA/
death when compared with both recreational sport (hazard 
ratio - HR=1.99, P=0.007) and inactive patients (HR=2.05, 
P=0.030). No increased risk of VTA/death was associated 
with recreational sport when compared with patients who 
were inactive (HR=1.03, P=0.930). Symptoms developed at 
an earlier age in patients who participated in competitive sport 
(30±12 years), when compared with patients who participated 
in recreational sport (38±17 years) (P=0.015) and inactive 
patients (41±11 years) (P=0.002) (Ruwald A-C et al, Eur 
Heart J 2015;36:1735-1743).
Rotterdam Study: Chronic Obstructive Pulmonary 
Disease (COPD) is Associated with an Increased Risk 
for Sudden Cardiac Death (SCD) / The Risk Especially 
Increases in Persons with Frequent Exacerbations 5 
Years After the Diagnosis of COPD
Among 13,471 subjects aged ≥45 years with up to 24 years 
of follow-up, 1615 having a diagnosis of COPD, there were 
551 cases of SCD. COPD was associated with an increased 
risk of SCD (hazard ratio - HR, 1.34). The risk particularly 
increased in the period 5.48 years after the diagnosis of 
COPD (HR 2.12) and increased further to a >three-fold 
higher risk in COPD subjects with frequent exacerbations 
during this period (HR 3.58) (Lahousse L et al, Eur Heart J 
2015;36:1754-1761).
VENTURE-AF: in Patients Undergoing Catheter 
Ablation (CA) for Atrial Fibrillation (AF), the Use of 
Uninterrupted Oral Rivaroxaban was Feasible and 
Event Rates Were Similar to those for Uninterrupted 
Vitamin K Antagonist (VKA) Therapy 
A total of 248 non-valvular AF patients (mean age 59.5 
years, 71% male, 74% paroxysmal AF, CHA2DS2-VASc 
score of 1.6) were randomized to uninterrupted rivaroxaban 
(20 mg qd) or to an uninterrupted VKA prior to CA and for 4 
weeks afterwards. The average total heparin dose used intra-
procedurally was slightly higher and mean ACT level attained 
slightly lower in rivaroxaban and VKA arms, respectively. The 
incidence of major bleeding was low (0.4%; 1 major bleed-
ing event). Thromboembolic events were also low (0.8%; 1 
ischemic stroke and 1 vascular death). All events occurred in 
the VKA arm and all after CA (Cappato R et al, Eur Heart J 
2015;36:1805-1811).
Review & Meta-Analysis: Digoxin is Associated with 
Increased Mortality in Patients Treated for Atrial 
Fibrillation (AF) or for Heart Failure (HF) / Negative 
Effects of Digoxin are Particularly Seen in the AF 
Population and Somewhat Less Unfavourable Effects in 
the HF Population
Meta-analysis of 19 reports (9 with AF patients, 7 with HF 
patients, and 3 with both) comprising 326,426 patients, indi-
cated that digoxin use was associated with an increased relative 
risk of all-cause mortality (hazard ratio - HR 1.21, P <0.01). 
Compared with subjects not receiving the drug, digoxin was 
associated with a 29% increased mortality risk (HR 1.29) in 
the subgroup of publications comprising 235,047 AF patients. 
Among 91,379 heart failure patients, digoxin-associated mortal-
ity risk increased by 14% (HR 1.14). The authors concluded 
that digoxin use is associated with an increased mortality risk, 
particularly among patients suffering from AF (Vamos M et 
al, Eur Heart J 2015;36:1831-1838).
PARADIGM-HF trial: Mode of Death / Treatment 
With Valsartan/Sacubitril or LCZ696 (Entresto), an 
Angiotensin Receptor-Neprilysin Inhibitor (ARNi), 
Compared With Enalapril in Chronic Heart Failure 
Patients Reduced Cardiovascular (CV) Death 
Primarily by Reducing Both Death Due to Worsening 
Heart Failure and Sudden Cardiac Death (SCD)
Over a median of 27 months, among 8399 patients with 
chronic heart failure, NYHA class II–IV, and left ventricular 
ejection fraction ≤40%, the majority of deaths were cardiovas-
cular (CV) (80.9%), and the risk of CV death was significantly 
reduced by treatment with ARNi (hazard ratio - HR 0.80, P 
<0.001). Among CV deaths, both SCD (HR 0.80, P=0.008) 
and death due to worsening heart failure (HR 0.79, P=0.034) 
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were reduced by treatment with ARNi compared with enalapril. 
Deaths attributed to other CV causes, including MI and stroke, 
were infrequent and distributed evenly between treatment 
groups, as were non-CV deaths (Desai AS et al, Eur Heart J 
2015; 36:1990-1997).
Dutch Registry: Secundum Atrial Septal Defect (ASD) 
is Associated with Reduced Survival in Adult Men
In a total of 2207 adult patients (mean age 44.8 years, 33% 
male), 102 deaths occurred during a cumulative follow-up of 
13,584 patient-years. Median survival was 79.7 years for men 
and 85.6 years for women with ASD. Compared with the age- 
and gender-matched general population, survival was lower for 
male, but not for female patients (P=0.015 and 0.766, respec-
tively). Men had a higher risk of conduction disturbances (odds 
ratio - OR=1.63) supraventricular dysrhythmias (OR=1.41), 
cerebro-vascular thromboembolic events (OR=1.53), and 
heart failure (OR=1.91) (Kuijpers JM et al, Eur Heart J 2015; 
36:2079-2086).
EMPHASIS-HF Trial: Post Hoc Analysis Indicates 
that Eplerenone is Safe, Improves Survival, and May 
Prevent Re-Admission When Initiated Soon After a 
Hospitalization for HF or Acute Coronary Syndromes 
in Patients With Systolic HF and Mild Symptoms
Post hoc analysis in 2338 patients (NYHA class II / left 
ventricular ejection fraction ≤35%) randomized to eplerenone 
within 180 days of a cardiovascular hospitalization (CVH) in-
dicated that most of the CVHs at a median of 42 days were for 
heart failure (HF) (N=1496, 64%), acute coronary syndromes 
(N=390, 16.7%), and arrhythmias (N=197, 7.2%). The relative 
rate reductions in CV death/CVH, and all-cause mortality were 
similar whether treatment was initiated <42 or 42+ days after 
qualifying CVH. Absolute rate reductions were −5.61 events 
per 100 patient × years in the <42 days group and −3.58 in 
the 42+ days group. The adverse effects of eplerenone were 
also unaffected by the time from the qualifying CVH (Girerd 
N et al, Eur Heart J 2015; 36:2310-2317).
PADIS-PE Trial: Among Patients With Pulmonary 
Embolism Receiving 6 Months of Anticoagulant, 
Extended Treatment to 18 Months Reduced the 
Composite Outcome of Recurrent Venous Thrombosis 
and Major Bleeding Compared With Placebo, But the 
Benefit was Lost after Stopping Anticoagulation
Among 371 adult patients who had experienced a first 
episode of symptomatic pulmonary embolism and had been 
treated initially for 6 months with a vitamin K antagonist, in 
those randomized to extended therapy or not, the primary 
outcome (recurrent venous thromboembolism or major bleed-
ing at 18 months) occurred in 6 of 184 patients (3.3%) in the 
warfarin group and in 25 of 187 (13.5%) in the placebo group 
(hazard ratio - HR, 0.22; P=0.001). Recurrent venous throm-
boembolism occurred in 3 patients in the warfarin group and 
25 patients in the placebo group (HR, 0.15); major bleeding in 
4 patients in the warfarin group and in 1 patient in the placebo 
group (HR, 3.96). Over 42 months, the composite outcome 
occurred in 33 patients (20.8%) in the warfarin group and in 
42 (24.0%) in the placebo group (HR, 0.75). Rates of recur-
rent venous thromboembolism, major bleeding, and unrelated 
death did not differ between groups (Couturaud F et al, JAMA 
2015;314:31-40).
AMETHYST-DN Trial: in Patients with Hyperkalemia 
and Diabetic Kidney Disease, Patiromer, a Potassium-
Binding Polymer, in Doses of 4.2-16.8 g bid Resulted in 
Significant Decreases in Serum Potassium Level After 
4 Weeks of Treatment, Lasting Through 52 Weeks
In 306 outpatients with type 2 diabetes (glomerular filtra-
tion rate, 15 to <60 mL/min/1.73 m2 and serum potassium 
>5.0 mEq/L), all receiving RAAS inhibitors, randomized to 
patiromer, the least squares mean reduction from baseline 
in serum potassium level at week 4 or time of first dose titra-
tion in patients with mild hyperkalemia was 0.35 mEq/L for 
the 4.2 g bid starting-dose group, 0.51 mEq/L for the 8.4 g 
bid starting-dose group, and 0.55 mEq/L for the 12.6 g bid 
starting-dose group. In those with moderate hyperkalemia, 
the reduction was 0.87 mEq/L for the 8.4 g bid starting-dose 
group, 0.97 mEq/L for the 12.6 g bid starting-dose group, and 
0.92 mEq/L for the 16.8 g bid starting-dose group (P <0 .001). 
From week 4 through week 52, significant mean decreases in 
serum potassium levels were observed at each monthly point in 
patients with mild and moderate hyperkalemia. Adverse events 
comprised hypomagnesemia (7.2%), constipation (6.3%), and 
hypokalemia (<3.5 mEq/L) (5.6%) (Bakris GL et al, JAMA 
2015;314:151-161).
Association Between Inadequate Blood Pressure 
Control and Increased Risk of Recurrent Intracerebral 
Hemorrhage (ICH)
Among 1145 of 2197 consecutive patients with ICH surviv-
ing at least 90 days and followed up for a median of 36.8 months, 
there were 102 recurrent ICH events among 505 survivors of 
lobar ICH and 44 recurrent ICH events among 640 survivors 
of nonlobar ICH. During follow-up adequate BP control was 
achieved on at least 1 measurement by 625 patients (54.6%) 
and consistently by 495 patients (43.2%). The event rate for 
lobar ICH was 84 per 1000 person-years among patients with 
inadequate BP control compared with 49 per 1000 person-years 
among patients with adequate BP control. For nonlobar ICH 
the event rate was 52 per 1000 person-years with inadequate 
BP control compared with 27 per 1000 person-years for patients 
with adequate BP control. Inadequate BP control was associ-
ated with higher risk of recurrence of both lobar ICH (hazard 
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ratio - HR, 3.53) and nonlobar ICH (HR, 4.23). Systolic BP 
during follow-up was associated with increased risk of both 
lobar ICH recurrence (HR, 1.33 per 10-mm Hg increase) and 
nonlobar ICH recurrence (HR, 1.54). Diastolic BP was associ-
ated with increased risk of nonlobar ICH recurrence (HR, 1.21 
per 10-mm Hg increase) but not with lobar ICH recurrence 
(HR, 1.36) (Biffi A et al, JAMA 2015; 314:904-912). 
Meta-Analysis for Treatment of In-Stent Restenosis 
(ISR)/ Two strategies should be considered: PCI with 
Everolimus Eluting Stents Because of the Better 
Angiographic and Clinical Results than with the Other 
Treatment Strategies, and Drug-Coated Balloons 
Because of their Ability to Provide Favourable Results 
Without Adding a New Stent Layer 
Meta-analysis of 27 trials comprising 5923 patients with 
in-stent restenosis indicated that PCI with everolimus-eluting 
stents was the most effective treatment for percent diameter 
stenosis, with a difference of −9% vs drug-coated balloons 
(DCB), −9.4% vs sirolimus-eluting stents, −10.2% vs paclitaxel-
eluting stents, −19.2% vs vascular brachytherapy, −23.4% vs 
bare metal stents, −24.2% vs balloon angioplasty, and −31.8% 
vs rotablation. DCB were ranked as the second most effective 
treatment, but without significant differences from sirolimus-
eluting (–0.2%) or paclitaxel-eluting (–1.2%) stents (Siontis 
GC et al, Lancet 2015; 386(9994):655–664).
DANAMI-3—PRIMULTI Trial: in Patients 
with STEMI and Multivessel Disease, Complete 
Revascularization Guided by FFR Measurements 
During the Index Admission Reduces the Risk of 
Future Events by Reducing Repeat Revascularizations 
After successful percutaneous coronary intervention (PCI) 
of the infarct-related artery, patients with STEMI (n=627) were 
randomly allocated either no further invasive treatment (n-313) 
or complete fractional flow reserve (FFR)-guided revasculariza-
tion (n=314) before discharge. Over a median of 27 months, 
events comprising the primary endpoint (all-cause mortality, 
non-fatal reinfarction, and ischemia-driven revascularization 
of lesions in non-infarct-related arteries) were recorded in 68 
(22%) patients who had PCI of the infarct-related artery only 
and in 40 (13%) patients who had complete revascularization 
(hazard ratio 0.56; p=0.004) (Engstrøm T et al, Lancet 2015; 
386(9994):665–671).
ADVICE Study: Adenosine Testing to Identify and 
Target Dormant Pulmonary Vein Conduction During 
Catheter Ablation of Atrial Fibrillation is a Safe and 
Effective Strategy to Improve Arrhythmia-Free Survival 
in Patients With Paroxysmal Atrial Fibrillation
Adenosine unmasked dormant pulmonary vein conduc-
tion in 284 (53%) of 534 patients. 102 (69.4%) of 147 patients 
with additional adenosine-guided ablation were free from 
recurrence compared with 58 (42.3%) of 137 patients with no 
further ablation, corresponding to an absolute risk reduction 
of 27.1% (p<0.0001) and a hazard ratio of 0.44 (p<0.0001). 
Of 115 patients without dormant pulmonary vein conduction, 
64 (55.7%) remained free from recurrences (p=0.0191). Se-
rious adverse events were similar in each group. One death 
(massive stroke) was deemed probably related to ablation in 
a patient included in the registry (Macle L et al, Lancet 2015; 
386(9994):672–679).
Important Review and Other Articles 
Non-compaction of the left ventricle (Hussein A et al, J Am 
Coll Cardiol 2015; 66:578-585), Duration of dual antiplatelet 
therapy (Montalescot G et al, J Am Coll Cardiol 2015; 66:832-
847), orthostatic hypotension (Ricci F et al, J Am Coll Cardiol 
2015; 66:848-860), Cardiac fibrosis in atrial fibrillation (Dzeshka 
MS et al, J Am Coll Cardiol 2015; 66:943-959), Cardiovascular 
toxicities associated with kinase inhibitors employed in cancer 
therapies (Li W et al, J Am Coll Cardiol 2015; 66:1160-1178), 
Leadless pacemakers (Miller MA et al, J Am Coll Cardiol 
2015; 66:1179-1189), Bridging anticoagulation (Rechenmacher 
SJ & Fang JC, J Am Coll Cardiol 2015; 66:1392-1403), 2015 
ACC/HRS/SCAI left atrial appendage occlusion device so-
cietal overview (Masoudi FA et al, J Am Coll Cardiol 2015; 
66:1497-1513), Atrial myopathy underlying atrial fibrillation 
(Goldberger JJ et al, Circulation 2015; 132:278-291), Inter-
national Task Force Consensus Statement on Treatment of 
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia 
(Corrado D et al, Circulation 2015; 132:441-453), AHA/ADA 
Update on Prevention of Cardiovascular Disease in Adults 
With Type 2 Diabetes Mellitus (Fox CS et al, Circulation 2015; 
132:691-718), Drug therapy for heart valve diseases (Bore JS & 
Sharma A, Circulation 2015; 132:1038-1045), Heparin-induced 
thrombocytopenia (Greinacher A, N Engl J Med 2015; 373:252-
261), Ischemic limb gangrene with pulses (Warkentin TE, N 
Engl J Med 2015; 373:642-655), Guide for monitoring patients 
receiving direct oral anticoagulants for stroke prevention in 
atrial Fibrillation (Gladstone DJ et al, Ann Intern Med 2015; 
163:382-385), Diabetic cardiomyopathy (Seferović PM & 
Paulus WJ, Eur Heart J 2015; 36:1718-1727), Electromagnetic 
interference in cardiac implants (Napp A et al, Eur Heart J 
2015; 36:1798-1804), Recommendations on pre-hospital and 
early hospital management of acute heart failure (Mebazaa A 
et al, Eur Heart J 2015; 36:1958-1966), Impact of antidiabetic 
agents on cardiovascular disease (Ferrannini E et al, Eur Heart 
J 2015; 36:2288-2296), Atrial flutter (Bun S-S et al, Eur Heart 
J 2015; 36:2356-2363), PCSK9 inhibitors (Shimada YJ et al, 
Eur Heart J 2015; 36:2415-2424), Treatment of atrial fibrilla-
tion (Prystowsky EN et al, JAMA 2015; 314:278-288), Diabetes 
advances in diagnosis and treatment (Natham DM, JAMA 
2015; 314:1052-1062), Hypertension (Poulter NR et al, Lancet 
2015; 386(9995):801–812), Non-compaction cardiomyopathy 
(Towbin JA et al, Lancet 2015; 386(9995):813–825).
